![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, November 05, 2022 7:29:02 PM
Regarding the NIH study and aviptadil, you are incorrect regarding the secondary endpoint. Here is an excerpt...
In this multicenter, randomized, placebo-controlled trial among critically ill patients with COVID-19 and respiratory failure, we did not reach statistical significance (OR, 1.6; 95% CI, 0.86–3.11) on the primary end point of being alive and free of respiratory failure at 60 days. There was a two-fold, statistically significant increased odds of day 60 survival (the key secondary end point) (p = 0.035).
Full study results....
https://journals.lww.com/ccmjournal/Fulltext/2022/11000/The_Use_of_IV_Vasoactive_Intestinal_Peptide.1.aspx?fbclid=IwAR0_feyIsWpE0jFpZASAjg_q5hJxVIT5GApgUYJ5_dqrJODYb8uat4s-RGc
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM